Edition:
India

Aptevo Therapeutics Inc (APVO.OQ)

APVO.OQ on NASDAQ Stock Exchange Global Select Market

3.34USD
2:29am IST
Change (% chg)

$-0.12 (-3.47%)
Prev Close
$3.46
Open
$3.50
Day's High
$3.50
Day's Low
$3.18
Volume
65,133
Avg. Vol
109,081
52-wk High
$4.85
52-wk Low
$1.18

Chart for

About

Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company's technology is the ADAPTIR (modular protein technology) platform. The Company... (more)

Overall

Beta: --
Market Cap(Mil.): $57.83
Shares Outstanding(Mil.): 21.42
Dividend: --
Yield (%): --

Financials

BRIEF-Aptevo Therapeutics Begins Patient Dosing In Phase 2 Clinical Trial Of Otlertuzumab In Peripheral T-Cell Lymphoma

* APTEVO THERAPEUTICS BEGINS PATIENT DOSING IN PHASE 2 CLINICAL TRIAL OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA Source text for Eikon: Further company coverage:

08 Jan 2018

BRIEF-Aptevo Therapeutics Announces Plans To Conduct Phase 2 Study Of Otlertuzumab In Peripheral T-Cell Lymphoma

* APTEVO THERAPEUTICS ANNOUNCES PLANS TO CONDUCT PHASE 2 STUDY OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA

28 Nov 2017

BRIEF-Aptevo Therapeutics files mixed shelf of up to $150 mln

* Aptevo Therapeutics Inc files for mixed shelf of up to $150 million - SEC filing‍​ Source text for Eikon: (http://bit.ly/2hvzJMI) Further company coverage:

13 Nov 2017

BRIEF-Aptevo Therapeutics reports third quarter 2017 financial results

* Aptevo Therapeutics reports third quarter 2017 financial results

10 Nov 2017

BRIEF-Aptevo Therapeutics and Alligator Bioscience announced further details of collaboration on ALG.APV-527​

* Aptevo Therapeutics Inc - ‍ co, Alligator Bioscience announced further details of companies' collaboration on ALG.APV-527​ Source text for Eikon: Further company coverage:

24 Oct 2017

BRIEF-APTEVO THERAPEUTICS ‍AMENDS TERMS OF CREDIT AGREEMENT

* APTEVO THERAPEUTICS INC - ‍AMENDED TERMS OF A CREDIT AGREEMENT INITIALLY EXECUTED WITH MIDCAP FINANCIAL TRUST IN AUGUST 2016​

29 Sep 2017

BRIEF-Aptevo Therapeutics and MorphoSys ends joint agreement to develop and commercialize MOR209/ES414

* Aptevo Therapeutics and MorphoSys end joint development and commercialization agreement for MOR209/ES414

01 Sep 2017

BRIEF-Aptevo Therapeutics signs agreement for up to $74.5 mln to sell Hyperimmune Commercial Products

* Aptevo Therapeutics signs agreement for up to $74.5 million to sell hyperimmune commercial products

01 Sep 2017

BRIEF-Aptevo and Alligator Bioscience start IND-enabling development activities immunotherapy drug

* Aptevo Therapeutics and Alligator Bioscience commence IND-enabling development activities for new bispecific immunotherapy candidate ALG.APV-527 Source text for Eikon: Further company coverage:

17 Aug 2017

BRIEF-Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy

* Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy

21 Jul 2017

Earnings vs. Estimates